Title

Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma

ORCiD

Nejat Düzgüneş: 0000-0001-6159-1391

Document Type

Article

Publication Title

Current Opinion in Molecular Therapeutics

ISSN

1464-8431

Volume

10

Issue

2

First Page

187

Last Page

195

Publication Date

4-1-2008

Abstract

Ark Therapeutics Group plc is developing sitimagene ceradenovec, a herpes simplex virus thymidine kinase/ganciclovir gene therapy utilizing an adenoviral vector, for the potential treatment of glioma. Sitimagene ceradenovec is currently undergoing a phase III clinical trial in malignant glioma patients. © The Thomson Corporation.

This document is currently not available here.

Share

COinS